7,14-hydroxy-docosapentaenoic acid

7,14-Dihydroxy-Docosapentaenoic Acid (MaR1n-3 DPA)

1. Identity and Chemical Characterization

1.1 Names and Nomenclature

7,14-Hydroxy-Docosapentaenoic Acid (abbreviated 7,14-HDPA) is an emerging bioactive lipid, classified as a specialized pro-resolving mediator (SPM), derived from omega-3 fatty acids. Its systematic chemical name, as confirmed by total synthesis, is (7S, 8E, 10E, 12Z, 14S, 16Z, 19Z)-7,14-dihydroxydocosa-8,10,12,16,19-pentaenoic acid. In the scientific literature on SPMs, it is most commonly referred to as MaR1n-3 DPA — designating it as the maresin-1 analogue derived from n-3 docosapentaenoic acid — a naming convention that reflects both its structural relationship to DHA-derived maresin 1 and its biosynthetic precursor. The compound may also appear under the designations 7,14-diHDPA, 7,14-dihydroxydocosapentaenoic acid, and 7R,14S-dihydroxydocosapentaenoic acid in various structural assignment contexts.

The naming of the n-3 DPA maresins, protectins, and resolvins is based on the chemically similar structures as the DHA-derived SPMs. The compound belongs to the broader family of the maresins, which are coined from "macrophage mediator in resolving inflammation." Maresin 1 (MaR1 or 7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid) is a macrophage-derived mediator of inflammation resolution coined from macrophage mediator in resolving inflammation; MaR1n-3 DPA is its structural congener derived from the n-3 DPA backbone rather than from DHA.

1.2 Parent Compound: n-3 Docosapentaenoic Acid (DPA)

The n-3 docosapentaenoic acid (n-3 DPA) is the less-studied n-3 long-chain polyunsaturated fatty acid (LCPUFA), compared to its counterparts eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Docosapentaenoic acid (DPA) (22:5n-3), a long-chain n-3 PUFA metabolite of EPA, is present in smaller amounts in fish. DPA appears principally derived from endogenous elongation from EPA, and DPA can also undergo retroconversion back to EPA. 7,14-HDPA is a di-oxygenated metabolite of this parent fatty acid, produced enzymatically when the immune system processes n-3 DPA at inflammatory sites.

The key chemical distinction between 7,14-HDPA and the structurally related DHA-derived maresin 1 is the absence of one double bond: the absence of the C4-C5 Z-configured double bond in n-3 DPA makes this PUFA incapable of biosynthesizing certain DHA-derived SPM congeners since this double bond is involved in the biosynthesis of RvD3, RvD4, and RvD6. The molecule contains five double bonds in its 22-carbon chain and carries hydroxyl groups at positions 7 and 14, giving it a precise three-dimensional geometry critical for receptor interaction.

1.3 Natural Sources

7,14-Hydroxy-Docosapentaenoic Acid (7,14-HDPA) is a specialized lipid compound derived from docosapentaenoic acid (DPA), an omega-3 fatty acid commonly found in fish oils and some plant sources. Because it is an enzymatically produced oxygenated metabolite, 7,14-HDPA is not itself a constituent of dietary fats in meaningful concentrations; rather, it is produced endogenously from dietary n-3 DPA by cells of the immune system.

The precursor, n-3 DPA, is obtained from dietary sources. Docosapentaenoic acid (DPA, 22:5n-3) has always been a part of healthy nutrition, since infants obtain almost as much DPA as DHA from human milk. Fish oil supplements and ingredients, oily fish, and grass-fed beef can serve as the primary DPA sources for the general population. Although the DPA levels in fish oils are substantially lower than those of EPA and DHA, concentrated DPA products are now becoming commercially available, and DPA-based drugs are under development. Circulating DPA levels correlate weakly with fish consumption, suggesting that DPA levels in humans are predominantly determined by endogenous metabolism rather than diet.

Present in food sources in non-negligible quantities, as well as in human milk, dietary n-3 DPA is of current interest both for its ability to increase EPA and DHA tissue status and for its specific or shared biological effects. 7,14-HDPA itself is detected endogenously during acute inflammation; the systemic levels of n-3 DPA and the new n-3 DPA products (including 17-HDPA, 14-HDPA, and 7-HDPA) were each elevated during acute inflammation in vivo, and chiral lipidomics of these n-3 DPA products demonstrated that the hydroxy groups in these products were predominantly in the S configuration, suggesting that each was produced via lipoxygenases.

1.4 Common Forms and Preparations

Since SPMs are biosynthesized only on the nano- to picogram scale, direct NMR analyses for their individual structural elucidations are not possible. Hence, mass spectrometry-based identification using multiple reaction monitoring (MRM) is used to establish the structures from biological sources. The inconvenience of this method is that it can only provide the basic structures without stereochemistry. Total chemical synthesis, which has been achieved for MaR1n-3 DPA, is therefore the primary route to obtaining amounts sufficient for detailed biological study.

Most commercially available SPMs are produced by chemical synthesis using low-activity and stability lipoxygenases, or chemical synthesis methods, which are low-yield, time-consuming and complicated processes that employ toxic chemicals. As a dietary supplement ingredient in isolation, 7,14-HDPA is not available in conventional consumer supplement forms. It is encountered in two research-accessible forms: (1) as a synthetic research-grade reference standard used in pharmacological experiments, and (2) as an endogenous molecule produced by the body following consumption of the omega-3 fatty acid precursor n-3 DPA via fish oil, oily fish, or concentrated DPA preparations. In the supplement industry, products marketed as containing "SPM concentrates" from enriched marine oils are the closest commercially available preparations that may contain this compound and/or its biosynthetic precursors, though the exact quantity of 7,14-HDPA in such preparations has not been standardized or consistently reported.

2. Traditional and Historical Use

The direct historical use of 7,14-HDPA as a distinct ingredient in traditional medicine is not documented. The compound was only identified and structurally characterized in 2013, and its total synthesis was first achieved in 2014. It is therefore a wholly modern scientific discovery with no independent ethnobotanical or traditional pharmacological history.

Fish oils, rich in omega-3 fatty acids, have been used in Scandinavian, Native American, and Asian cultures for promoting general health, easing inflammation, and supporting joint and cardiovascular wellbeing. The therapeutic benefits attributed to these oils are now understood to be partly due to their transformation into SPMs like 7,14-HDPA, which help resolve inflammation and promote tissue healing. The use of fish and marine oils in traditional societies thus constitutes an indirect historical precedent for exposure to the precursor fatty acids from which 7,14-HDPA is derived, but traditional practitioners had no knowledge of, and made no claims specific to, this oxygenated metabolite.

Oxygenated metabolites or oxylipins with highly specific stereochemical structures derived mainly from EPA, DPA, and DHA, termed "specialized pro-resolving mediators," are reported to have potent anti-inflammatory and immunoregulatory actions at concentrations in the nanomolar to picomolar range. Their structures have been conserved in evolution from diatoms to flatworms to fish to humans, where they are present in all major organ systems. The evolutionary conservation of these mediators underscores their deep biological importance even though their chemical identity was unknown until the modern era.

3. Discovery, Structural Elucidation, and Synthesis

3.1 Initial Discovery (2013)

Using functional-metabololipidomics and in vivo systems, endogenous n-3 docosapentaenoic (DPA) acid was found to be converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins, protectins, and maresins, termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E,19Z-docosapentaenoic acid (RvD1n-3 DPA) and 7,14-dihydroxy-8,10,12,16Z,19Z-docosapentaenoic acid (MaR1n-3 DPA) and related bioactive products.

In 2013, Dalli et al. reported that n-3 docosapentaenoic acid (n-3 DPA) was converted biosynthetically in both human and murine leukocytes to several new SPMs. One of the products identified was denoted MaR1n-3 DPA, given its relation to maresin 1. This SPM was produced in pico- to nanogram amounts in vivo. The initial structural assignment of MaR1n-3 DPA was based on biosynthetic results and LC-MS/MS fragmentation data. The exact stereochemical determination of the double bond geometry in the conjugated triene system and the absolute configurations of the C-7 and C-14 groups remained to be established.

3.2 Total Synthesis and Configurational Confirmation (2014)

The first total synthesis of the lipid mediator MaR1n-3 DPA was achieved in 12% overall yield over 11 steps. The stereoselective preparation was based on a Pd-catalyzed sp³–sp³ Negishi cross-coupling reaction and a stereocontrolled Evans–Nagao acetate aldol reaction. LC-MS/MS results with synthetic material matched the biologically produced compound.

Matching experiments between synthetic and human macrophage MaR1n-3 DPA demonstrated that the synthetic material co-elutes with the naturally occurring compound, establishing the absolute configuration to be (7S,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-8,10,12,16,19-pentaenoic acid. This configurational confirmation was essential, as the biological potency of SPMs is highly stereodependent.

4. Biochemistry and Mechanisms of Action

4.1 Biosynthetic Pathway

These lipid mediators govern the resolution of inflammation as potent and stereoselective agonists toward individual G-protein-coupled receptors, resulting in potent anti-inflammatory activities demonstrated in many human disease models. Specialized pro-resolving mediators are oxygenated polyunsaturated products formed in stereoselective and distinct biosynthetic pathways initiated by various lipoxygenase and cyclooxygenase enzymes.

SPMs include lipoxins, resolvins (E-series, D-series, and n-3 DPA-derived), protectins, and maresins, all of which are actively synthesized during acute inflammation — mostly by monocytes/macrophages and neutrophils — through the action of 5-, 12-, and 15-lipoxygenase (5-, 12-, and 15-LOX), and acetylated or nitrosylated cyclooxygenase (COX)-2.

The biosynthesis of 7,14-HDPA (MaR1n-3 DPA) from n-3 DPA parallels the biosynthesis of DHA-derived maresin 1. In a reaction scheme similar to the one for DHA-derived maresins, 13,14(S)-epoxy-docosapentaenoic acid (13,14(S)-epoxy-DPAn-3) can be hydrolysed by an epoxide hydrolase to form either 7(R),14(S)-dihydroxy-docosapentaenoic acid (MaR1n-3 DPA) or 13,14(S)-dihydroxy-docosapentaenoic acid (MaR2n-3 DPA). The proposed biosynthetic pathway thus involves initial lipoxygenase-mediated insertion of molecular oxygen into n-3 DPA, formation of an epoxide intermediate at the 13,14-position, and subsequent epoxide hydrolase-mediated ring opening to yield the 7,14-dihydroxy product.

SPMs represent a class of pro-resolving, anti-pain, and anti-inflammatory lipids naturally derived from omega-3 and omega-6 fatty acids that help healing without compromising the body's ability to defend against inflammatory insults (e.g., infection or injury). SPMs are a genus with several families of potent endogenous bioactive products derived from precursor essential fatty acids EPA, DHA, arachidonic acid (ARA) and docosapentaenoic acid (DPA) that are biosynthesized by positional and stereospecific incorporation of one, two, or three molecules of molecular oxygen into a polyunsaturated fatty acid (PUFA) using EPA, DHA, ALA and DPA as substrates into a catalyzed reaction involving fatty acid lipoxygenases, cyclooxygenase type-2, when acetylated by aspirin, and several cytochrome P450 oxidases.

4.2 Receptor Pharmacology and Signaling

SPMs display highly potent agonist effects in vivo, often in the low nanomolar range, by acting as ligands on individual G-protein coupled receptors (GPCRs). MaR1n-3 DPA and MaR2n-3 DPA are named after maresin-1 (derived from DHA) as they share an alcohol group at C14 and are proposed to possess similar anti-inflammatory and proresolving potency and activity as maresin-1.

The mechanisms through which resolvins and related SPMs exert their biological actions involve down-regulation of NF-κB and AP-1 activity and are thought to be mediated via G-protein coupled receptors (GPCRs). Endogenous SPMs display potent anti-inflammatory and pro-resolving bioactions in the low nanomolar to picomolar range without causing undesirable side effects.

It has become apparent that a novel aspect of the resolution process is that SPMs are able to induce changes in the phenotype of macrophages toward a pro-resolution state. In the context of 7,14-HDPA specifically, macrophage responses include enhanced phagocytosis and efferocytosis (clearance of apoptotic cells), both of which are fundamental to active inflammation resolution.

4.3 Stereoselectivity of Action

An isomer of maresin 1, 7S,14S-diHDHA, was less potent, indicating stereoselective actions in vitro and in vivo. This principle extends to MaR1n-3 DPA: the (7S,14S) configuration confirmed by total synthesis is the biologically active form. The sensitivity of biological activity to stereochemistry underscores that the compound's pharmacology is receptor-mediated rather than purely physicochemical, and synthetic analogs must match the natural stereochemistry to replicate bioactivities.

5. Scientific Evidence by Area of Use

5.1 Inflammation Resolution

The foundational evidence base for 7,14-HDPA (MaR1n-3 DPA) derives predominantly from preclinical in vitro and in vivo studies. Each n-3 DPA-SPM displayed protective actions from second organ injury and reduced systemic inflammation in ischemia-reperfusion. The n-3 DPA-SPMs, including RvD1n-3 DPA and MaR1n-3 DPA, each exerted potent leukocyte-directed actions in vivo.

With human leukocytes each n-3 DPA-SPM reduced neutrophil chemotaxis, adhesion and enhanced macrophage phagocytosis. The resolvins, protectins and maresins are coined specialized pro-resolving mediators (SPM) that by definition limit further neutrophil recruitment to the site of inflammation and promote macrophage clearance of debris, apoptotic cells and bacteria.

This novel lipid mediator displayed potent pro-resolving properties stimulating macrophage efferocytosis of apoptotic neutrophils. MaR1n-3 DPA was next assayed for its potential to enhance human macrophage efferocytosis, a highly important pro-resolution hallmark. The results provided clear evidence for the potent bioactions of the compound and its corresponding ethyl ester in stimulating efferocytosis of apoptotic human neutrophils by macrophages.

Evidence strength: Preclinical — in vitro (human leukocytes and macrophages) and animal in vivo studies. No randomized controlled trials specifically testing 7,14-HDPA as an isolated compound in human subjects with inflammatory disease endpoints have been published as of the current literature. Although large-scale human clinical trials specifically evaluating 7,14-HDPA are still limited, early results are promising and indicate potential advantages when incorporated into functional foods or dietary supplements.

5.2 Ischemia-Reperfusion and Organ Protection

Each n-3 DPA-SPM displayed protective actions from second organ injury and reduced systemic inflammation in ischemia-reperfusion. This finding, in murine in vivo models, suggests that MaR1n-3 DPA may limit bystander organ damage during ischemic events by curtailing excessive inflammatory leukocyte infiltration.

In addition, the SPMs exert potent actions in promoting wound repair and tissue regeneration as well as dampening inflammatory pain. These tissue-protective effects are consistent with the broader biology of the maresin family and have been characterized in animal model systems.

Evidence strength: Murine in vivo models only. No human clinical evidence specifically for 7,14-HDPA in ischemia-reperfusion has been published.

5.3 Cardiovascular Biology

Recently, n-3 docosapentaenoic acid (DPA), which was until then only regarded as a biosynthetic intermediate in the formation of DHA from EPA, was found to be converted to structurally distinct bioactive mediators that reprogram the host immune response. Available evidence addresses the biological actions of these novel n-3 DPA-derived autacoids particularly as they pertain to the vascular system.

Investigation of the diurnal regulation of specialized proresolving mediators in humans and their role in controlling peripheral blood leukocyte and platelet activation revealed that plasma concentrations of n-3 docosapentaenoic acid-derived D-series resolvins (RvDn-3 DPA) were regulated in a diurnal manner. The production and regulation of these mediators was markedly altered in patients at risk of myocardial infarct. While this study addressed the D-series resolvins rather than MaR1n-3 DPA specifically, it demonstrates that the n-3 DPA-derived SPM family, as a whole, is clinically detectable and dysregulated in cardiovascular risk states.

During blood coagulation, a characteristic SPM cluster has been detected that consists of resolvin E1 (RvE1), RvD1, RvD5, lipoxin B4, and maresin 1 at bioactive concentrations (0.1 to 1 nM), together with eicosanoids such as prostaglandins, thromboxanes and leukotrienes. The detection of related maresins at these concentrations in vascular contexts confirms the physiological relevance of this lipid class.

For the parent compound DPA: a few studies have observed inverse associations between circulating DPA and risk of coronary events. DPA has been shown to have a positive role in reducing the expression of inflammatory genes (inflammation in the walls of blood vessels is thought to play a role in the development of atherosclerotic plaques leading to cardiovascular disease), thereby improving cardiovascular health. Whether these effects are mediated, in part, through conversion to 7,14-HDPA is biologically plausible but not yet directly demonstrated in human studies.

Purified DPA is available, and DPA is a precursor of biologically active molecules, but much remains to be learned about the effects of DPA in humans. In epidemiologic studies, erythrocyte DPA did not predict risk for total mortality, sudden cardiac death, or other relevant cardiovascular events, and, more importantly, did not improve prediction of these events when included along with EPA and DHA.

Evidence strength: Indirect. Epidemiological associations pertain to the parent compound DPA, not 7,14-HDPA directly. In vitro and early human observational studies on related DPA-derived SPMs are suggestive but not conclusive.

5.4 Intestinal Inflammation and Inflammatory Bowel Disease

The resolution of inflammation is an active process orchestrated by specialized proresolving lipid mediators that limit the host response within the affected tissue; failure of effective resolution may lead to tissue injury. Because persistence of inflammatory signals is a main feature of chronic inflammatory conditions including inflammatory bowel diseases (IBDs), targeted liquid chromatography-tandem mass spectrometry-based metabololipidomics was used to identify SPMs from n-3 polyunsaturated fatty acids in human IBD colon biopsies, quantifying a significant up-regulation of the resolvin and protectin pathway compared with normal gut tissue.

RvD5n-3 DPA and PD1n-3 DPA are protective against intestinal inflammation and intestinal diseases including inflammatory bowel disease. The identification of n-3 DPA-derived SPMs in human colon biopsy tissue from IBD patients, as well as animal model protection data, represents the strongest evidence of intestinal relevance within the DPA-derived SPM family. It is not yet established whether MaR1n-3 DPA specifically recapitulates these effects in gut tissue.

Evidence strength: Preliminary. Human tissue-level metabololipidomics showing the DPA-derived SPM pathway is active in the inflamed human gut, combined with murine in vivo protection data for related mediators. Clinical therapeutic trials are lacking.

5.5 Immune Modulation and Macrophage Biology

The decrease in inflammation associated with n-3 DPA seems to come mainly from lipid mediators and mainly the specialized pro-resolving mediator (SPM) (maresins, protectins, resolvins). Indeed, incubation of human macrophages with Protectin D1n-3 DPA increased the monocyte differentiation, the phagocytic activity of macrophages, and the apoptosis of neutrophils, which are key factors in the resolution of inflammation.

With human leukocytes, these n-3 DPA-SPMs reduced neutrophil chemotaxis, adhesion, and enhanced macrophage phagocytosis. These actions have been demonstrated using isolated human leukocytes incubated with synthetic MaR1n-3 DPA at 1 nM concentration, providing direct ex vivo human cellular evidence for the compound's immunomodulatory activity.

Neutrophils were incubated with vehicle or n-3 DPA products (1 nM, 15 min, 37°C, pH 7.45) prior to loading on ChemoTx chambers and assessing chemotaxis towards IL-8 (100 ng/ml, 90 min, 37°C, pH 7.45). Macrophages were incubated with vehicle or n-3 DPA products (1 nM, 15 min, 37°C, pH 7.45) prior to addition of fluorescently labeled zymosan (1:10 macrophages to zymosan).

Evidence strength: Moderate for the in vitro human cellular level. These are mechanistic studies confirming direct effects on isolated human immune cells, not controlled clinical trials. Translation to whole-body human therapeutic outcomes remains to be established.

5.6 Human Supplementation with the Precursor (DPA) and Downstream SPM Production

One double-blind crossover study in humans directly examined what happens to SPM profiles when n-3 DPA is supplemented. Shifts in circulating levels of n-3 and n-6 PUFA-derived bioactive lipid mediators were quantified by an unbiased liquid chromatography-tandem mass spectrometry lipidomic approach. Plasma was obtained from human subjects before and after 7 days of supplementation with pure n-3 DPA, n-3 EPA, or placebo (olive oil). DPA supplementation increased the SPM resolvin D5n-3 DPA (RvD5n-3 DPA) and maresin (MaR)-1, the DHA vicinal diol 19,20-dihydroxy-DPA, and n-6 PUFA-derived 15-keto-PGE2.

This study is notable as it provides the only human interventional evidence demonstrating that dietary precursor supplementation with n-3 DPA elevates the circulating concentrations of DPA-derived SPMs. The finding that MaR-1 (DHA-derived) was elevated alongside the DPA-derived resolvins reflects the complex interplay among omega-3 fatty acid metabolic pools. The study did not directly measure MaR1n-3 DPA (7,14-HDPA) as a distinct endpoint.

Additionally, a human study using enriched marine oil supplements found that supplementation established the relationship between supplementation and peripheral SPM concentrations, and investigated the relationship between changes in plasma SPM concentrations and peripheral blood platelet and leukocyte responses.

Evidence strength: One small double-blind crossover human study demonstrating precursor-mediated elevation of related DPA-derived SPMs; no randomized controlled trials assessing clinical health outcomes through 7,14-HDPA elevation exist.

5.7 Obesity, Metabolic Disease, and Lipid Metabolism

Studies of hydroxylated DPA derivatives, including diHEP-DPA and TH-DPA, demonstrated amelioration of HFD-induced obesity in mice and also reduced obesity-induced chronic inflammation in the liver tissues of obese mice. These SPMs were reported to reduce the secretion of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-12 in adipose tissue, and decrease MCP-1– and LTB4–induced migration of macrophages toward adipocytes.

Similar work is now showing that DPA also possesses lipid metabolism improving effects similar to EPA and DHA in improving cholesterol and TG levels. A recent in vivo study demonstrated that DPA can reduce non-HDL cholesterol by 50% in hamsters.

Evidence strength: Preliminary animal (in vivo rodent) data only for metabolic and lipid effects. No human clinical data exist for 7,14-HDPA specifically in metabolic disease.

5.8 Vascular Inflammation

Research into DHA-derived maresin 1, the closest structural analog, provides additional mechanistic context. Maresins have been found to exert anti-inflammatory and pro-resolving responses in macrophages, neutrophils, and bronchial epithelial cells and impart beneficial actions in murine models of peritonitis and colitis. MaR1 was investigated as a modulator of TNF-α effects, with examination of monocyte adhesion, oxidant stress, and intracellular inflammatory signaling pathways, and MaR1 attenuated TNF-α-induced monocyte adhesion and reactive oxygen species (ROS) generation in both endothelial cells and vascular smooth muscle cells.

Studies find that the maresins inhibit certain pro-inflammatory functions in human neutrophils and macrophages in vitro, that MaR1 and MaR2 reduce the entry of blood neutrophils into the inflamed peritoneum in a mouse model, and that MaR1 promotes the resolution of allergic pulmonary inflammation in a mouse model as well as wound healing in a planaria worm model. These studies have not yet translated to human physiology or pathology.

Evidence strength: In vitro (human cells) and murine models for the DHA-derived analog; structural and mechanistic parallels with MaR1n-3 DPA are proposed but the translation to human disease outcomes for 7,14-HDPA specifically requires clinical investigation.

6. Body Systems and Health Areas Associated with 7,14-HDPA

• Immune System: Modulation of neutrophil chemotaxis and adhesion; enhancement of macrophage phagocytosis and efferocytosis; macrophage polarization toward pro-resolution phenotype.
• Cardiovascular System: Potential attenuation of vascular inflammation; diurnal regulation of DPA-derived SPMs disrupted in patients at risk of myocardial infarct; indirect associations through parent DPA compound and cardiovascular risk markers.
• Gastrointestinal System: DPA-derived SPMs identified in human IBD colon tissue; related congeners (PD1n-3 DPA, RvD5n-3 DPA) shown protective in murine intestinal inflammation models.
• Metabolic System: Preclinical data suggesting anti-inflammatory effects in adipose tissue and liver in obese murine models for related hydroxylated DPA derivatives.
• Pain Pathways: The SPMs exert potent actions in promoting wound repair and tissue regeneration as well as dampening inflammatory pain.
• Tissue Repair and Wound Healing: Macrophage-mediated clearance of apoptotic cells and debris as a critical component of the resolution-repair sequence.

7. Dosage Forms and Reported Dosages

7,14-HDPA is not commercially available as a standalone dietary supplement in a standardized dosage form. In biochemical research settings, it is handled as a synthetic compound administered at nanomolar to picomolar concentrations in cell culture experiments. The following dosages and contexts are reported directly from the primary literature:

• In vitro (human leukocytes and macrophages): Neutrophils and macrophages were incubated with n-3 DPA products at 1 nM, 15 min, 37°C, pH 7.45. This concentration (1 nanomolar) is the reported effective in vitro concentration for MaR1n-3 DPA and related congeners in human immune cell assays.
• In vivo (murine): Treatment with maresin 1 at 2 µg/kg (another DHA-derived SPM) was shown to improve insulin sensitivity, increase adiponectin gene expression and Akt phosphorylation in adipose tissues, and attenuate adipose tissue inflammation in both genetic and diet-induced obese mouse models. No equivalent dose has been reported specifically for MaR1n-3 DPA in published in vivo studies.
• Human precursor supplementation: Human subjects received 7 days of supplementation with pure n-3 DPA, n-3 EPA, or placebo (olive oil) in the only published human supplementation crossover study. The specific dose of pure n-3 DPA used in this trial was not retrievable from the abstract-level data available, and the primary source document (PMC5067251) should be consulted for exact dosimetry.

No clinical trials have established a therapeutic dosage range for 7,14-HDPA itself, as isolated clinical use of this specific molecule has not been formally studied.

8. Safety Considerations and Interactions

8.1 Endogenous Nature and Theoretical Safety Profile

7,14-HDPA is an endogenous lipid mediator produced physiologically by the human body during the resolution phase of acute inflammation. Endogenous SPMs display potent anti-inflammatory and pro-resolving bioactions in the low nanomolar to picomolar range without causing undesirable side effects. The compound's endogenous status and the picomolar-to-nanomolar bioactive range suggests a favorable intrinsic safety profile at physiological concentrations, as it is a molecule the body itself produces and degrades.

8.2 Absence of Direct Human Safety Data

No human safety studies, formal toxicology assessments, or adverse event reports specific to the administration of isolated 7,14-HDPA as a supplement are available in the published literature. Safety information is therefore extrapolated from the parent compound (n-3 DPA) and the broader fish oil/omega-3 context.

8.3 Parent Compound Safety Context

Hazard identification for supplemental DHA (the closest well-studied related compound) has focused on bleeding complications (including bleeding time, platelet function, and blood clotting parameters), glucose homeostasis, blood lipid profile, markers of lipid peroxidation, immune function, pregnancy endpoints, and safety, tolerability, and adverse events. The risk of spontaneous bleeding was selected as the critical effect on which to base the upper limit for supplemental DHA alone. In the absence of adequate data to characterize a dose-response relationship and identify a reference point, no formal upper limit for supplemental DHA alone can be established for any population group.

8.4 Stereochemical Specificity and Potential Concerns with Synthetic Analogs

An isomer of maresin 1, 7S,14S-diHDHA, was less potent than the natural stereoisomer, indicating stereoselective actions in vitro and in vivo. This highlights the importance of stereochemical purity in any synthetic preparation intended for biological use. Impure or racemic preparations would contain stereoisomers of unknown activity and tolerability.

8.5 Scalability and Commercial Production Challenges

Most commercially available SPMs are produced by chemical synthesis using low-activity and stability lipoxygenases, or chemical synthesis methods, which are low-yield, time-consuming, and complicated processes that employ toxic chemicals. These manufacturing constraints mean that commercially available preparations containing 7,14-HDPA may vary in purity, isomeric composition, and concentration, introducing uncertainty about safety and potency that does not exist for well-characterized, long-studied supplements.

8.6 Potential Interactions

No specific drug or supplement interaction data for isolated 7,14-HDPA are available. At the level of its precursor DPA, it is notable that novel n-3 DPA-derived pro-resolving mediators are vasculoprotective and mediate the actions of statins in controlling inflammation, suggesting a potential pharmacological interaction between the DPA-derived SPM pathway and statin-class lipid-lowering drugs. Whether statins specifically upregulate the 7,14-HDPA pathway or primarily act through other DPA-derived mediators requires further clarification. No specific safety concerns arising from such interactions have been reported in the human literature.

Studies in mammals, platelets, and cell cultures have demonstrated that DPA reduces platelet aggregation and improves lipid metabolism. Given this antiplatelet action of the parent fatty acid, caution in combination with anticoagulants or antiplatelet drugs is theoretically warranted, though not formally studied for 7,14-HDPA specifically.

9. Evidence Gaps and Research Outlook

The n-3 DPA-derived families of SPMs should be attractive as substrates for receptor and metabolism studies, where less knowledge is available at this point. As of today, only the metabolite of PD1n-3 DPA, named 22-OH-PD1n-3 DPA, has been reported and studied. The biological evaluations of simpler chemical synthetic analogs of the known n-3 DPA-derived SPMs will also be of future interest.

While the parent compound DPA has garnered attention in nutritional research, 7,14-HDPA, as a specific hydroxylated derivative, represents a more recent focus of scientific investigation. Preliminary in vitro and animal studies suggest that hydroxylated DPA derivatives, including 7,14-HDPA, may play a role in modulating inflammatory pathways and supporting cellular signaling processes.

Key unresolved questions include: (1) the specific G-protein-coupled receptor(s) mediating MaR1n-3 DPA's actions; (2) its pharmacokinetics and bioavailability when administered orally; (3) whether dietary supplementation with n-3 DPA produces therapeutically meaningful concentrations of 7,14-HDPA at tissue sites of inflammation; and (4) whether the compound has clinical efficacy in human inflammatory, cardiovascular, or metabolic disease. Currently, no pharmacological treatments are approved to stimulate endogenous SPM biosynthesis for promoting inflammation resolution.

Research over the last 25 years related to structural elucidations and biological investigations of the specialized pro-resolving mediators has spurred great interest in targeting these endogenous products in total synthesis. These lipid mediators govern the resolution of inflammation as potent and stereoselective agonists toward individual G-protein-coupled receptors, resulting in potent anti-inflammatory activities demonstrated in many human disease models. The field is advancing rapidly toward clinical translation, and 7,14-HDPA is considered a member of this therapeutically promising family of molecules.

References

• Dalli J, Colas RA, Serhan CN. "Novel n-3 Immunoresolvents: Structures and Actions." Scientific Reports 2013;3:1940. PMC3672887
• Tungen JE, Aursnes M, Dalli J, Arnardottir H, Serhan CN, Hansen TV. "Total Synthesis of the Anti-inflammatory and Pro-resolving Lipid Mediator MaR1n-3 DPA Utilizing an sp3–sp3 Negishi Cross-coupling Reaction." Chemistry 2014;20(45):14575–14578. PMC4232850
• Aursnes M, Tungen JE, Vik A, Colas R, Serhan CN, Hansen TV. "Total Synthesis of the Lipid Mediator PD1n-3 DPA: Configurational Assignments and Anti-inflammatory and Pro-resolving Actions." Journal of Natural Products 2014;77(4):910–916. PMC4000582
• Tungen JE, Primdahl KG, Aursnes M, Vik A, Hansen TV. "Biology and Total Synthesis of n-3 Docosapentaenoic Acid-Derived Specialized Pro-Resolving Mediators." Molecules 2024;29(12):2833. PMC11206527
• Colas RA, Dalli J, Serhan CN et al. "Divergent Shifts in Lipid Mediator Profile Following Supplementation with n-3 Docosapentaenoic Acid and Eicosapentaenoic Acid." FASEB Journal 2016. PMC5067251
• Buela-Casal M et al. "Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection." Proceedings of the National Academy of Sciences 2017;114(12). PNAS
• Colas RA, Souza PR, Walker ME et al. "Impaired Production and Diurnal Regulation of Vascular RvDn-3 DPA Increase Systemic Inflammation and Cardiovascular Disease." Circulation Research 2018;122:855–863.
• Reactome Pathway Database. "Epoxide hydrolase hydrolyses 13,14-epoxy-DPAn-3 to MaR1n-3 DPA or MaR2n-3 DPA." R-HSA-9025998.
• LIPID MAPS Lipid Web. "Protectins, Resolvins and Maresins – Specialized Pro-Resolving Mediators."
• Hansen TV, Dalli J, Serhan CN. "The novel lipid mediator PD1n-3 DPA: An overview of the structural elucidation, synthesis, biosynthesis and bioactions." Prostaglandins Other Lipid Mediators 2017;133:103–110. PubMed 28602942
• Synthesis, Structural Confirmation, and Biosynthesis of 22-OH-PD1n-3 DPA. PMC6767081.
• Drouin G et al. "The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family." Biochimie 2019;159:36–48.
• Kaur G, Cameron-Smith D, Garg M, Sinclair AJ. "Dietary sources, current intakes, and nutritional role of omega-3 docosapentaenoic acid." Lipid Technology 2015. PMC4467567
• A review of the biologic and pharmacologic role of docosapentaenoic acid n-3. PMC4162505.
• Mozaffarian D, Wu JH. "Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events." Journal of the American College of Cardiology 2011;58(20):2047–2067.
• Mozaffarian D, Lemaitre RN, King IB et al. "(n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?" Journal of Nutrition 2012;142(3):614S–625S. PMC3278271
• Ho KJ et al. "The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells." PLOS ONE 2014;9(11):e113480.
• Jeon YH et al. "The docosahexaenoic acid derivatives, diHEP-DPA and TH-DPA, synthesized via recombinant lipoxygenase, ameliorate disturbances in lipid metabolism and liver inflammation in high fat diet-fed mice." Life Sciences 2022;289:120196.
• Frankincense preparation promotes formation of inflammation-resolving lipid mediators by manipulating lipoxygenases in human innate immune cells. PMC10794731.
• EFSA NDA Panel. "Scientific Opinion on the tolerable upper intake level for supplemental docosahexaenoic acid." EFSA Journal 2025. PMC12802091
• Wikipedia. "Maresin." (For structural nomenclature cross-reference only.)